Johnson & Johnson Announces Updated Financials and 2023 Guidance Following Completion of the Kenvue Separation

Company expects increased 2023 Reported Sales Growth of 7.0% - 8.0%, Operational Sales Growth of 7.5% - 8.5%, and Adjusted Operational Sales Growth of 6.2% - 7.2%; Figures exclude the COVID-19...

Related Keywords

Joaquin Duato ,Kenvue Inc ,Johnson Consumer Health ,Johnson ,Abiomed ,Consumer Health ,Consumer Health Company ,Company Consumer Health ,Exchange Commission ,Chief Executive ,Shares Outstanding ,Euro Average Rate ,Average Shares Outstanding ,Adjusted Diluted ,Private Securities Litigation Reform Act ,New Consumer Health Company ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Consolidated Statement ,Millions Except Per Share Figures ,Discontinued Operations ,Basic Shares ,Millions Except Per Share Data ,Continuing Operations ,Asset Amortization ,Net Earnings ,Before Tax ,Income Before Tax ,Quarter July ,Quarter Jan ,Months Jan ,Markets ,